Stoke Therapeutics Inc Forecast, price target & analysts
Stoke Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Stoke Therapeutics Inc Classifications & Recommendation:
Stoke Therapeutics Inc Price Target
| Target Price | $23.88 |
| Price | $7.99 |
| Potential |
198.81%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Stoke Therapeutics Inc 2026 .
The average Stoke Therapeutics Inc target price is $23.88.
This is
198.81%
register free of charge
$47.00
488.24%
register free of charge
$15.00
87.73%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Stoke Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Stoke Therapeutics Inc stock has an average upside potential 2026 of
198.81%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 8.78 | 17.92 |
| 29.25% | 104.13% | |
| EBITDA Margin | -1,253.30% | -608.76% |
| 54.27% | 51.43% | |
| Net Margin | -1,435.05% | -596.68% |
| 29.38% | 58.42% |
10 Analysts have issued a sales forecast Stoke Therapeutics Inc 2024 . The average Stoke Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Stoke Therapeutics Inc EBITDA forecast 2024. The average Stoke Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Stoke Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Stoke Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.38 | -2.02 |
| 8.46% | 15.13% | |
| P/E | negative | |
| EV/Sales | 10.56 |
5 Analysts have issued a Stoke Therapeutics Inc forecast for earnings per share. The average Stoke Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Stoke Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Stoke Therapeutics Inc...
Current Stoke Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital | Locked ➜ Locked | Locked | Feb 19 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 18 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 18 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 08 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 08 2025 |
| Chardan Capital | Locked ➜ Locked | Locked | Dec 20 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Dec 10 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 18 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 18 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Chardan Capital: Locked ➜ Locked
|
Dec 20 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Dec 10 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
